Cargando…

Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor

Magnetic resonance (MR) methods enable noninvasive, regional tumor therapy response assessment, but associations between MR parameters, underlying biology, and therapeutic effects must be investigated. The aim of this study was to investigate response assessment efficacy and biological associations...

Descripción completa

Detalles Bibliográficos
Autores principales: Montelius, Mikael, Spetz, Johan, Jalnefjord, Oscar, Berger, Evelin, Nilsson, Ola, Ljungberg, Maria, Forssell-Aronsson, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772005/
https://www.ncbi.nlm.nih.gov/pubmed/29331677
http://dx.doi.org/10.1016/j.tranon.2017.12.003
_version_ 1783293331994836992
author Montelius, Mikael
Spetz, Johan
Jalnefjord, Oscar
Berger, Evelin
Nilsson, Ola
Ljungberg, Maria
Forssell-Aronsson, Eva
author_facet Montelius, Mikael
Spetz, Johan
Jalnefjord, Oscar
Berger, Evelin
Nilsson, Ola
Ljungberg, Maria
Forssell-Aronsson, Eva
author_sort Montelius, Mikael
collection PubMed
description Magnetic resonance (MR) methods enable noninvasive, regional tumor therapy response assessment, but associations between MR parameters, underlying biology, and therapeutic effects must be investigated. The aim of this study was to investigate response assessment efficacy and biological associations of MR parameters in a neuroendocrine tumor (NET) model subjected to radionuclide treatment. Twenty-one mice with NETs received (177)Lu-octreotate at day 0. MR experiments (day −1, 1, 3, 8, and 13) included T2-weighted, dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) and relaxation measurements (T1/T2*). Tumor tissue was analyzed using proteomics. MR-derived parameters were evaluated for each examination day and for different radial distances from the tumor center. Response assessment efficacy and biological associations were evaluated using feature selection and protein expression correlations, respectively. Reduced tumor growth rate or shrinkage was observed until day 8, followed by reestablished growth in most tumors. The most important MR parameter for response prediction was DCE-MRI–derived pretreatment signal enhancement ratio (SER) at 40% to 60% radial distance, where it correlated significantly also with centrally sampled protein CCD89 (association: DNA damage and repair, proliferation, cell cycle arrest). The second most important was changed diffusion (D) between day −1 and day 3, at 60% to 80% radial distance, where it correlated significantly also with peripherally sampled protein CATA (association: oxidative stress, proliferation, cell cycle arrest, apoptotic cell death). Important information regarding tumor biology in response to radionuclide therapy is reflected in several MR parameters, SER and D in particular. The spatial and temporal information provided by MR methods increases the sensitivity for tumor therapy response.
format Online
Article
Text
id pubmed-5772005
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-57720052018-01-22 Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor Montelius, Mikael Spetz, Johan Jalnefjord, Oscar Berger, Evelin Nilsson, Ola Ljungberg, Maria Forssell-Aronsson, Eva Transl Oncol Original article Magnetic resonance (MR) methods enable noninvasive, regional tumor therapy response assessment, but associations between MR parameters, underlying biology, and therapeutic effects must be investigated. The aim of this study was to investigate response assessment efficacy and biological associations of MR parameters in a neuroendocrine tumor (NET) model subjected to radionuclide treatment. Twenty-one mice with NETs received (177)Lu-octreotate at day 0. MR experiments (day −1, 1, 3, 8, and 13) included T2-weighted, dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) and relaxation measurements (T1/T2*). Tumor tissue was analyzed using proteomics. MR-derived parameters were evaluated for each examination day and for different radial distances from the tumor center. Response assessment efficacy and biological associations were evaluated using feature selection and protein expression correlations, respectively. Reduced tumor growth rate or shrinkage was observed until day 8, followed by reestablished growth in most tumors. The most important MR parameter for response prediction was DCE-MRI–derived pretreatment signal enhancement ratio (SER) at 40% to 60% radial distance, where it correlated significantly also with centrally sampled protein CCD89 (association: DNA damage and repair, proliferation, cell cycle arrest). The second most important was changed diffusion (D) between day −1 and day 3, at 60% to 80% radial distance, where it correlated significantly also with peripherally sampled protein CATA (association: oxidative stress, proliferation, cell cycle arrest, apoptotic cell death). Important information regarding tumor biology in response to radionuclide therapy is reflected in several MR parameters, SER and D in particular. The spatial and temporal information provided by MR methods increases the sensitivity for tumor therapy response. Neoplasia Press 2018-01-11 /pmc/articles/PMC5772005/ /pubmed/29331677 http://dx.doi.org/10.1016/j.tranon.2017.12.003 Text en © 2017 Oncoinvent AS http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Montelius, Mikael
Spetz, Johan
Jalnefjord, Oscar
Berger, Evelin
Nilsson, Ola
Ljungberg, Maria
Forssell-Aronsson, Eva
Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title_full Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title_fullStr Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title_full_unstemmed Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title_short Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
title_sort identification of potential mr-derived biomarkers for tumor tissue response to (177)lu-octreotate therapy in an animal model of small intestine neuroendocrine tumor
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772005/
https://www.ncbi.nlm.nih.gov/pubmed/29331677
http://dx.doi.org/10.1016/j.tranon.2017.12.003
work_keys_str_mv AT monteliusmikael identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT spetzjohan identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT jalnefjordoscar identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT bergerevelin identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT nilssonola identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT ljungbergmaria identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor
AT forssellaronssoneva identificationofpotentialmrderivedbiomarkersfortumortissueresponseto177luoctreotatetherapyinananimalmodelofsmallintestineneuroendocrinetumor